Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...

It has a plasma half-life of approximately 12 h, is cleared by both renal and hepatic routes, and undergoes limited CYP metabolism, resulting in low potential drug–drug interactions. When given ...